We are live on ! Find out more
ALDR

Alder Biopharmaceuticals
ALDR

Delisted

ALDR was delisted on the 21st of October, 2019.

Back to rankings

132 hedge funds and large institutions have $803M invested in Alder Biopharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 62 increasing their positions, 24 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

158% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 24

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

35% more capital invested

Capital invested by funds: $595M → $803M (+$208M)

22% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 23

3% more funds holding

Funds holding: 128 → 132 (+4)

22% less call options, than puts

Call options by funds: $1.86M | Put options by funds: $2.39M

Holders
132
Holders Change
+4
Holders Change %
+3.13%
% of All Funds
3.29%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.1%
New
28
Increased
62
Reduced
24
Closed
23
Calls
$1.86M
Puts
$2.39M
Net Calls
-$532K
Net Calls Change
+$4.38M

Top Buyers

1
RG
Redmile Group
California
+$44.3M
2
State Street
State Street
Massachusetts
+$18.3M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$14.6M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.7M
5
PA
Pinnacle Associates
New York
+$12.6M

Top Sellers

1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$22.7M
2
AllianceBernstein
AllianceBernstein
Tennessee
-$14.7M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.8M
4
PHS
PFM Health Sciences
California
-$9.55M
5
AAMU
Amundi Asset Management US
Massachusetts
-$5.36M
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
26
Senzar Asset Management
New York
$7.85M +$870K +83,400 +15%
Brown Advisory
27
Brown Advisory
Maryland
$7.03M +$372K +35,630 +7%
Schroder Investment Management Group
28
Schroder Investment Management Group
United Kingdom
$6.72M +$6.12M +586,979 New
Dimensional Fund Advisors
29
Dimensional Fund Advisors
Texas
$6.6M +$4.11M +393,872 +272%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$6.32M +$1.03M +99,093 +24%
AC
31
Ascend Capital
California
$6.17M +$5.26M +504,175 New
AG
32
Artal Group
Luxembourg
$6.13M +$2.09M +200,000 +67%
PP
33
PDT Partners
New York
$5.4M +$4.59M +440,488 New
JP Morgan Chase
34
JP Morgan Chase
New York
$4.81M +$1.92M +184,097 +78%
IG
35
ING Group
Netherlands
$4.29M +$156K +15,000 +4%
DCM
36
DAFNA Capital Management
California
$4.24M +$1.3M +125,000 +57%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$3.86M +$864K +82,869 +36%
Massachusetts Financial Services
38
Massachusetts Financial Services
Massachusetts
$3.67M +$1.58M +151,809 +103%
Charles Schwab
39
Charles Schwab
California
$3.19M +$678K +64,988 +33%
Deutsche Bank
40
Deutsche Bank
Germany
$2.98M +$801K +76,778 +46%
BCPEM
41
Bain Capital Public Equity Management
Massachusetts
$2.28M +$1.94M +186,040 New
Wells Fargo
42
Wells Fargo
California
$2.12M +$394K +37,826 +28%
NLVP
43
New Leaf Venture Partners
New York
$2.1M – – –
TCIM
44
TIAA CREF Investment Management
New York
$2.03M +$2.45K +235 +0.1%
VRS
45
Virginia Retirement Systems
Virginia
$2.02M +$1.72M +165,300 New
SIM
46
Spark Investment Management
New York
$1.97M +$1.68M +161,000 New
Barclays
47
Barclays
United Kingdom
$1.82M +$1.41M +135,490 +1,029%
Citigroup
48
Citigroup
New York
$1.53M +$956K +91,687 +274%
Bank of America
49
Bank of America
North Carolina
$1.43M -$42.9K -4,118 -3%
CS
50
Candriam SCA
Luxembourg
$1.43M – – –
1
2
3 4 5

ALDR Hedge Fund Activity: Q3 2017 in Review

132 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q3 2017, worth a combined $803M — up 35% from $595M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new ALDR positions and 23 closed out — a net gain of 5 holders — while 62 added to existing stakes and 24 trimmed.

The largest buyer was Redmile Group, adding an estimated $44.3M. The largest seller was Janus Henderson Group, cutting an estimated $22.7M.

  • 132 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q3 2017, up from 128 in Q2 2017.
  • Funds reported $803M of Alder Biopharmaceuticals stock for Q3 2017, up 35% quarter-over-quarter.
  • 28 funds opened new Alder Biopharmaceuticals positions in Q3 2017 and 23 closed out, a net change of +5 holders.
  • The largest Alder Biopharmaceuticals buyer in Q3 2017 was Redmile Group, an estimated $44.3M added.
  • The largest Alder Biopharmaceuticals seller in Q3 2017 was Janus Henderson Group, an estimated $22.7M sold.

Based on aggregated 13F filings for Q3 2017.